A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets ... but some face patent expirations in the near-to-medium term, while other, newer products are ...

Global Partners LP (GLP) shares soared 6.8% in the last trading ... This compares to the stock's 14.1% gain over the past four weeks. The units’ surge can be attributed to strategic development ...

Hy-Vee Dietitian Hannah Anderson reviews GLP-1 receptor agonists (Ozempic, Wegovy and Rybelsus) and the importance of evidence-based nutrition guidance while taking them. Consuming adequate ...

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama/Getty The Food and Drug Administration has approved Ozempic to reduce the ...